会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Manipulating nitrosative stress to upregulate nitrosative stress defenses
    • 控制亚硝化压力以上调亚硝酸胁迫防御
    • US06359004B1
    • 2002-03-19
    • US09690989
    • 2000-10-18
    • Jonathan S. StamlerOwen W. Griffith
    • Jonathan S. StamlerOwen W. Griffith
    • A61K31195
    • A61K31/00A61K31/195A61K31/255C07C381/10Y02A50/473
    • Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth (for example, certain cancers, restenosis, benign prostatic hypertrophy) by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include &agr;-alkyl-S-alkyl-homocysteine sulfoximines wherein the &agr;-alkyl contains 2 to 8 carbon atoms, and the S-alkyl- contains 1 to 10 carbon atoms. In another invention herein, mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include, for example, repeated administrations of low doses of manipulators of nitrosative stress so that the subject treated has increased tolerance to nitrosative stress. In still another invention, mammals are treated for protozoal infections by systemic administration of L-buthionine-S-sulfoximine and agent that increases nitrosative stress.
    • 哺乳动物通过施用亚硝化应激的机械手来治疗感染或与病理性增殖的哺乳动物细胞生长(例如某些癌症,再狭窄,良性前列腺肥大)相关的病症,以选择性地杀死或减少微生物或蠕虫的生长,从而导致 感染或用微生物或病理增殖的哺乳动物细胞感染的宿主细胞。 新型药剂包括α-烷基-S-烷基 - 高半胱氨酸亚砜,其中α-烷基含有2-8个碳原子,并且S-烷基含有1-10个碳原子。 在本文的另一发明中,需要治疗需要增加的亚硝酸应激防御的哺乳动物被治疗,例如由于具有短暂性脑缺血发作而处于卒中风险的人。 增加亚硝化应激防御的治疗包括例如重复施用低剂量的亚硝化应激的操纵者,使得所治疗的受试者具有增加的对亚硝化应激的耐受性。 在另一个发明中,哺乳动物通过全身施用L-丁硫氨酸-S-亚磺酰亚胺和增加亚硝化压力的试剂来治疗原生动物感染。
    • 2. 发明授权
    • Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically, proliferating cells or to upregulate nitrosative stress defenses
    • 控制亚硝化压力以杀死病理微生物,病理性蠕虫和病理性增殖细胞或上调亚硝化应激防御
    • US06180824B2
    • 2001-01-30
    • US09361167
    • 1999-07-27
    • Jonathan S. StamlerOwen W. Griffith
    • Jonathan S. StamlerOwen W. Griffith
    • C07C6108
    • A61K31/00A61K31/195A61K31/255C07C381/10Y02A50/473
    • Mammals are treated for infection or for conditions associated with pathologically proliferating mammalian cell growth (for example, certain cancers, restenosis, benign prostatic hypertrophy) by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include &agr;-alkyl-S-alkyl-homocysteine sulfoximines wherein the &agr;-alkyl contains 2 to 8 carbon atoms, and the S-alkyl- contains 1 to 10 carbon atoms. In another invention herein, mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include, for example, repeated administrations of low doses of manipulators of nitrosative stress so that the subject treated has increased tolerance to nitrosative stress. In still another invention, mammals are treated for protozoal infections by systemic administration of L-buthionine-S-sulfoximine and agent that increases nitrosative stress.
    • 哺乳动物通过施用亚硝化胁迫的操纵者来治疗感染或与病理增殖的哺乳动物细胞生长(例如某些癌症,再狭窄,良性前列腺肥大)相关的病症,以选择性地杀死或减少微生物或蠕虫的生长,从而导致 感染或用微生物或病理增殖的哺乳动物细胞感染的宿主细胞。 新型药剂包括α-烷基-S-烷基 - 高半胱氨酸亚砜,其中α-烷基含有2-8个碳原子,并且S-烷基含有1-10个碳原子。 在本文的另一发明中,需要治疗需要增加的亚硝酸应激防御的哺乳动物被治疗,例如由于具有短暂性脑缺血发作而处于卒中风险的人。 增加亚硝化应激防御的治疗包括例如重复施用低剂量的亚硝化应激的操纵者,使得所治疗的受试者具有增加的对亚硝化应激的耐受性。 在另一个发明中,哺乳动物通过全身施用L-丁硫氨酸-S-亚磺酰亚胺和增加亚硝化压力的试剂来治疗原生动物感染。
    • 3. 发明授权
    • Manipulating nitrosative stress to kill pathologic microbes, pathologic
helminths and pathologically proliferating cells or to upregulate
nitrosative stress defenses
    • 控制亚硝化压力以杀死病理微生物,病理蠕虫和病理增殖细胞或上调亚硝酸胁迫防御
    • US6057367A
    • 2000-05-02
    • US852490
    • 1997-05-07
    • Jonathan S. StamlerOwen W. Griffith
    • Jonathan S. StamlerOwen W. Griffith
    • A61K31/00A61K31/195A61K31/255C07C381/10
    • A61K31/00A61K31/195A61K31/255C07C381/10
    • Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth (for example, certain cancers, restenosis, benign prostatic hypertrophy) by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include .alpha.-alkyl-S-alkyl-homocysteine sulfoximines wherein the .alpha.-alkyl contains 2 to 8 carbon atoms, and the S-alkyl-contains 1 to 10 carbon atoms. In another invention herein, mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include, for example, repeated administrations of low doses of manipulators of nitrosative stress so that the subject treated has increased tolerance to nitrosative stress. In still another invention, mammals are treated for protozoal infections by systemic administration of L-buthionine-S-sulfoximine and agent that increases nitrosative stress.
    • 哺乳动物通过施用亚硝化胁迫的机械手来治疗感染或与病理性增殖的哺乳动物细胞生长(例如某些癌症,再狭窄,良性前列腺肥大)相关的病症,以选择性地杀死或减少微生物或蠕虫的生长,从而导致 感染或用微生物或病理增殖的哺乳动物细胞感染的宿主细胞。 新型试剂包括α-烷基-S-烷基 - 高半胱氨酸亚砜,其中α-烷基含有2-8个碳原子,并且S-烷基含有1-10个碳原子。 在本文的另一发明中,需要治疗需要增加的亚硝酸应激防御的哺乳动物被治疗,例如由于具有短暂性脑缺血发作而处于卒中风险的人。 增加亚硝化应激防御的治疗包括例如重复施用低剂量的亚硝化应激的操纵者,使得所治疗的受试者具有增加的对亚硝化应激的耐受性。 在另一个发明中,哺乳动物通过全身施用L-丁硫氨酸-S-亚磺酰亚胺和增加亚硝化压力的试剂来治疗原生动物感染。
    • 5. 发明授权
    • Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
    • 控制亚硝化压力以杀死病理微生物,病理蠕虫和病理增殖细胞或上调亚硝酸胁迫防御
    • US07022737B2
    • 2006-04-04
    • US10417238
    • 2003-04-17
    • Jonathan S. StamlerOwen W. Griffith
    • Jonathan S. StamlerOwen W. Griffith
    • A61K31/17A61K31/195
    • A61K31/00A61K31/195A61K31/255C07C381/10Y02A50/473
    • Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include α-alkyl-S-alkyl-homocysteine sulfoximines wherein the α-alkyl contains 2 to 8 carbon atoms, and the S-alkyl contains 1 to 10 carbon atoms. Mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include repeated administrations of low doses of manipullators of nitrosative stress so that subject treated has increased tolerance to nitrosative stress. Mammals are treated for protozoal infections by systemic administration of L-buthionine-S-sulfoximine and agent that increases nirtrosative stress.
    • 哺乳动物通过施用亚硝化应激的操纵者来治疗感染或与病理增殖的哺乳动物细胞生长相关的病症,以选择性地杀死或减少引起感染的微生物或蠕虫或感染微生物或病理学的宿主细胞的生长 增殖哺乳动物细胞。 新型药剂包括α-烷基-S-烷基 - 高半胱氨酸亚砜,其中α-烷基含有2-8个碳原子,并且S-烷基含有1-10个碳原子。 治疗需要增加的亚硝酸应激防御的哺乳动物被治疗,例如由于具有短暂性脑缺血发作而处于卒中风险的人。 增加亚硝化应激防御的治疗包括重复施用低剂量的亚硝化应激的操纵者,使得受治疗的受试者具有增加的对亚硝化压力的耐受性。 哺乳动物通过全身施用L-丁硫氨酸-S-亚磺酰亚胺和增加内分泌压力的药剂来治疗原虫感染。
    • 6. 发明授权
    • Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
    • 控制亚硝化压力以杀死病理微生物,病理蠕虫和病理增殖细胞或上调亚硝酸胁迫防御
    • US06608110B2
    • 2003-08-19
    • US10013455
    • 2001-12-13
    • Jonathan S. StamlerOwen W. Griffith
    • Jonathan S. StamlerOwen W. Griffith
    • A61K31195
    • A61K31/00A61K31/195A61K31/255C07C381/10Y02A50/473
    • Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include &agr;-alkyl-S-alkyl-homocysteine sulfoxmines wherein the &agr;-alkyl contains 2 to 8 carbon atoms, and the S-alkyl contains 1 to 10 carbon atoms. Mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include repeated administrations of low doses of manipulators of nitrosative stress so that the subject treated has increased tolerance to nitrosative stress. Mammals are treated for protozoal infections by systemic administration of L-buthionine-S-sulfoximine and agent that increases nitrosative stress.
    • 哺乳动物通过施用亚硝化应激的操纵者来治疗感染或与病理增殖的哺乳动物细胞生长相关的病症,以选择性地杀死或减少引起感染的微生物或蠕虫或感染微生物或病理学的宿主细胞的生长 增殖哺乳动物细胞。 新型试剂包括α-烷基-S-烷基 - 高半胱氨酸亚砜,其中α-烷基含有2-8个碳原子,并且S-烷基含有1-10个碳原子。 治疗需要增加的亚硝酸应激防御的哺乳动物被治疗,例如由于具有短暂性脑缺血发作而处于卒中风险的人。 增加亚硝化应激防御的治疗包括重复施用低剂量的亚硝化应激的操纵者,使得受治疗的受试者具有增加的对亚硝化应激的耐受性。 哺乳动物通过全身施用L-丁硫氨酸-S-亚磺酰亚胺和增加亚硝化压力的试剂来治疗原生动物感染。
    • 9. 发明授权
    • Heme binding compounds and use thereof
    • 血红素结合化合物及其用途
    • US5663364A
    • 1997-09-02
    • US550645
    • 1995-10-31
    • Owen W. GriffithKrishnaswamy Narayanan
    • Owen W. GriffithKrishnaswamy Narayanan
    • C07D333/20A61K31/18A61K31/195A61K31/198A61P9/00A61P25/00A61P37/06A61P43/00C07C281/16C07C323/25C07C335/04C07C335/08C07D233/64C07D333/22C07D207/335
    • C07C335/08C07D333/22
    • Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.NH when there is a single bond between the omega carbon and Q, and physiologically acceptable acid addition salts thereof.
    • 用于治疗低血压,炎症,中风和恢复对α1肾上腺素能激动剂的作用的血管收缩敏感性的精氨酸形成一氧化氮的抑制剂是生理活性化合物,包括N-3取代的鸟氨酸或Nε-取代的赖氨酸部分或单烷基碳 - 其中R是(CH 2)y CH 3或H,R'是CH 2或C(H)(CH 2)y CH 3,R“是CH 2 或C(H)(CH 2)y CH 3,y在0至5之间,x是0或1,并且其中R,R'和R“中没有一个或只有一个在鸟氨酸或赖氨酸部分上提供烷基取代基, 其中当ω-碳和Q之间存在双键时,Q是血红素结合部分和/或含硫结合部分,Q'是-NH 2,并且当ω碳之间存在单键时,Q'为= NH 和Q,及其生理上可接受的酸加成盐。